EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Coming of Age: Targeting Cyclin K in Cancers

Yi Xiao iD, Jixin Dong iD

Cells · 2023

DOI: 10.3390/cells12162044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Yi Xiao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE …. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclins and cyclin-dependent kinases (CDKs) play versatile roles in promoting the hallmarks of cancer. Therefore, cyclins and CDKs have been widely studied and targeted in cancer treatment, with four CDK4/6 inhibitors being approved by the FDA and many other inhibitors being examined in clinical trials. The specific purpose of this review is to delineate the role and therapeutic potential of Cyclin K in cancers. Studies have shown that Cyclin K regulates many essential biological processes, including the DNA damage response, mitosis, and pre-replicative complex assembly, and is critical in both cancer cell growth and therapeutic resistance. Importantly, the druggability of Cyclin K has been demonstrated in an increasing number of studies that identify novel opportunities for its use in cancer treatment. This review first introduces the basic features and translational value of human cyclins and CDKs. Next, the discovery, phosphorylation targets, and related functional significance of Cyclin K-CDK12/13 complexes in cancer are detailed. This review then provides a summary of current Cyclin K-associated cancer studies, with an emphasis on the available Cyclin K-targeting drugs. Finally, the current knowledge gaps regarding the potential of Cyclin K in cancers are discussed, along with interesting directions for future investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansCell Transformation, NeoplasticCyclin-Dependent KinasesCyclinsKnowledge

Stichwörter der Autor:innen

CDKCyclin Kcancercyclindegraderinhibitorphosphorylation

Substanzen

Cyclin-Dependent KinasesCyclins

Autor:innen und Institutionen

  • Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.

ORCID-Profile: Yi Xiao, Jixin Dong

Förderung

  • NCI NIH HHS
  • Institutes of Health (NIH)

Zitieren

APA

Xiao, Y., & Dong, J. (2023). Coming of Age: Targeting Cyclin K in Cancers. Cells. https://doi.org/10.3390/cells12162044

Vancouver

Xiao Y, Dong J. Coming of Age: Targeting Cyclin K in Cancers. Cells. 2023. doi:10.3390/cells12162044

BibTeX
@article{Xiao2023,
  author = {Xiao, Yi and Dong, Jixin},
  title = {Coming of Age: Targeting Cyclin K in Cancers},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12162044}
}
Kostenlos starten →